Capstan Medical TMVR Study: FIH
Key facts
- Who runs it
- Capstan Medical
- Where
- Australia, Brazil, Chile, and New Zealand4 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 10 people, planned
- Started
- 24 Feb 2025
- Expected to end
- Dec 2031
- Type of study
- Interventional
- Treatments tested
- Capstan System transcatheter mitral valve replacement
- Record updated
- 28 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Age ≥ 18 years at the time of consent
- Moderate-severe (3+) or severe (4+) mitral regurgitation
- NYHA II or greater symptoms despite optimal medical treatment
- The local multi-disciplinary heart team agrees that TMVR is the preferred treatment over surgical intervention or other available treatment options (such as TEER)
- Ability and willingness to provide written informed consent prior to any study related procedure(s)
Who cannot take part
- Prior mitral valve intervention that would interfere with the appropriate placement of the Capstan Valve
- Any percutaneous coronary, carotid, or other endovascular intervention within 30 days prior to procedure
- Myocardial infarction within 30 days prior to procedure
- Subject is on the waiting list for a heart transplant or has had a prior heart transplant
- Inability to tolerate anticoagulation or antiplatelet therapies
- Severe right ventricular dysfunction or severe tricuspid valve disease
- Cardiac resynchronization therapy (CRT) device implanted within 30 days of procedure
- Active endocarditis, other ongoing infection requiring antibiotic therapy
- Stroke or transient ischemic attack (TIA) within 30 days of procedure
- Active peptic ulcer or active gastrointestinal bleeding
- Severe pulmonary arterial hypertension with fixed PASP greater than 85mmHg
- End-stage renal failure on dialysis
- Known allergy to antiplatelet therapy, heparin, or to device materials
- LVEF less than 20%
- Pregnant (Participants of childbearing age are required to have a negative pregnancy test)
- Anatomic features (e.g., annular dimensions, neo-LVOT area, transfemoral and transseptal access, excessive MAC) unsuitable for the Capstan System
- Severe aortic valve stenosis or regurgitation
- Severe mitral stenosis
- Evidence of intracardiac thrombus, vegetation, or mass
- Life expectancy less than 1 year
- Absence of appropriate venous access
- Unable to have transesophageal echocardiography
- Unwillingness to complete the required follow-up visits
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a prospective, multi-center, non-randomized first in human study to evaluate the safety and feasibility of the Capstan Medical TMVR System for intervention in adults with moderate-severe or greater mitral regurgitation who are not surgical candidates.
The group in the trial
- ImplantTreatment being tested
Participants who pass all screening criteria will undergo a percutaneous procedure for the implantation of a permanent mitral valve replacement device. Participants will be followed for 5 years to evaluate safety and feasibility of Capstan Medical TMVR System for mitral valve replacement in humans with predominantly regurgitant mitral valves who are symptomatic and who are not good surgical candidates.
Treatment: Capstan System transcatheter mitral valve replacement
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Capstan Medical TMVR Study: First-in-Human Evaluation of the Capstan TMVR System
- Record updated
- 28 August 2026